News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
18,019 Results
Type
Article (3095)
Company Profile (4)
Press Release (14920)
Section
Business (7071)
Career Advice (96)
Deals (998)
Drug Delivery (13)
Drug Development (2659)
Employer Resources (13)
FDA (588)
Job Trends (627)
News (11062)
Policy (1041)
Tag
Academia (69)
Alliances (1492)
Alzheimer's disease (20)
Antibody-drug conjugate (ADC) (8)
Approvals (593)
Artificial intelligence (8)
Bankruptcy (9)
Best Places to Work (363)
Biosimilars (14)
Breast cancer (18)
Cancer (66)
Cardiovascular disease (12)
Career advice (73)
CAR-T (6)
Cell therapy (13)
Clinical research (2135)
Collaboration (21)
COVID-19 (101)
C-suite (19)
Data (22)
Diagnostics (55)
Drug discovery (6)
Drug pricing (19)
Earnings (1511)
Editorial (6)
Employer branding (7)
Employer resources (12)
Events (1223)
Executive appointments (54)
FDA (606)
Funding (18)
Gene therapy (16)
GLP-1 (42)
Government (185)
Healthcare (379)
IgA nephropathy (6)
Immunology and inflammation (6)
Infectious disease (102)
Interviews (17)
IPO (286)
IRA (11)
Job creations (277)
Job search strategy (73)
Layoffs (63)
Legal (348)
Lung cancer (5)
Medical device (61)
Medtech (61)
Mergers & acquisitions (704)
Metabolic disorders (14)
Neuroscience (30)
NextGen: Class of 2025 (242)
Non-profit (61)
Northern California (35)
Obesity (10)
Opinion (36)
Patents (12)
People (3498)
Phase I (617)
Phase II (862)
Phase III (948)
Pipeline (20)
Podcasts (6)
Policy (14)
Postmarket research (148)
Preclinical (188)
Prostate cancer (10)
Radiopharmaceuticals (28)
Rare diseases (7)
Real estate (173)
Regulatory (587)
Research institute (68)
Resumes & cover letters (24)
Series A (9)
Southern California (21)
Startups (271)
The Weekly (6)
United States (276)
Vaccines (12)
Venture capitalists (5)
Weight loss (8)
Date
Last 7 days (15)
Last 30 days (66)
Last 365 days (844)
2025 (119)
2024 (840)
2023 (819)
2022 (2045)
2021 (1817)
2020 (1403)
2019 (1200)
2018 (965)
2017 (1221)
2016 (911)
2015 (985)
2014 (735)
2013 (602)
2012 (636)
2011 (611)
2010 (623)
Location
Africa (51)
Asia (1294)
Australia (182)
California (68)
Canada (35)
China (6)
Connecticut (6)
Delaware (6)
Europe (4474)
Massachusetts (88)
New Jersey (24)
New York (17)
North Carolina (15)
Northern California (35)
Pennsylvania (10)
South America (51)
Southern California (21)
Texas (7)
Washington State (6)
18,019 Results for "novartis".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
The closures follow Novartis’s acquisition of MorphoSys earlier this year.
December 19, 2024
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
February 11, 2025
·
2 min read
·
Tristan Manalac
Patents
Novartis Scrambles to Squelch Copycats as Generics Gain Ground
Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto.
January 17, 2025
·
2 min read
·
Tristan Manalac
Earnings
Novartis Eyes More Bolt-On Deals in 2025 as Q4 Earnings Easily Beat Consensus
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
January 31, 2025
·
2 min read
·
Tristan Manalac
Legal
Novartis Loses Appeal to Bar Entresto Generic From U.S. Market
Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset that brought in more than $6 billion in net global sales last year.
December 5, 2024
·
2 min read
·
Tristan Manalac
Mergers & Acquisitions
Novartis CEO Promises More Deals of Up to $5B, With an Eye for Early Science
Novartis has disclosed roughly $19.4 billion in deals in the past five years. CEO Vas Narasimhan says there’s more to come.
November 21, 2024
·
2 min read
·
Annalee Armstrong
Radiopharma
Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space
The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.
November 18, 2024
·
2 min read
·
Nick Paul Taylor
Earnings
Novartis Gets Q3 Beat on Strong Cosentyx Sales, But Pluvicto Disappoints
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali.
October 29, 2024
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030
Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand its new modality pipeline to ensure long-term business sustainability.
November 21, 2024
·
2 min read
·
Tristan Manalac
Approvals
Novartis Secures First-Line CML Expansion for Scemblix, Projects $3B in Peak Sales
Scemblix was granted accelerated approval by the FDA for the treatment of certain patients newly diagnosed with chronic myeloid leukemia. The expanded indication increases the eligible patient population by approximately four times, according to Novartis.
October 30, 2024
·
2 min read
·
Tristan Manalac
1 of 1,802
Next
